source
- Novo downplays contested obesity drug as rivals report promising cancer combos and Incyte makes $2 billion blood-disease acquisitionNovo executives said the obesity drug they once fought Pfizer for is less impressive than expected, downplaying its potential. Revolution Medicines and Tango Therapeutics reported a high response…
- Tango and Revolution report high response rates in early pancreatic cancer combo trialTango Therapeutics and Revolution Medicines tested a combination of Tango's drug vopimetostat with Revolution's daraxonrasib in an early-stage clinical trial for pancreatic cancer. The study enroll…